Federal Register / Vol. 87, No. 60 / Tuesday, March 29, 2022 / Notices 18017 

corr.elizabeth@epa.gov, or by phone at 

(202) 564–3798, preferably at least 10 

days prior to the meeting to allow as 

much time as possible to process your 

request. 

National Drinking Water Advisory 

Council: NDWAC was created by 

Congress on December 16, 1974, as part 

of the Safe Drinking Water Act (SDWA) 

of 1974, Public Law 93–523, 42 U.S.C. 

300j–5, and is operated in accordance 

with the provisions of the Federal 

Advisory Committee Act (FACA), 5 

U.S.C. App. 2. NDWAC was established 

to advise, consult with, and make 

recommendations to the EPA 

Administrator on matters relating to 

activities, functions, policies, and 

regulations under SDWA. General 

information concerning NDWAC is 

available at: https://www.epa.gov/ 

ndwac. 

Jennifer L. McLain, 

Director, Office of Ground Water and Drinking 

Water. 

[FR Doc. 2022–06576 Filed 3–28–22; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL COMMUNICATIONS 

COMMISSION 

[OMB 3060–1223; FR ID 78823] 

Information Collection Being Reviewed 

by the Federal Communications 

Commission 

AGENCY: Federal Communications 

Commission. 

ACTION: Notice; correction. 

SUMMARY: The Federal Communications 

Commission published a document in 

the Federal Register of November 16, 

2021 (86 FR 56713), concerning a 

request for comments for the 

information collection Payment 

Instructions from the Eligible Entity 

Seeking Reimbursement from the TV 

Broadcaster Relocation Fund. The 

document omitted the dates, addresses 

and for further information sections 

from this notice. 

Correction 

In the Federal Register of November 

16, 2021, in FR Document 2021–24912, 

on page 63381, in the first column, 

correct the DATES, ADDRESSES and FOR

FURTHER INFORMATION CONTACT caption 

to read as follows: 

DATES: Written PRA comments should 

be submitted on or before May 31, 2022. 

If you anticipate that you will be 

submitting comments, but find it 

difficult to do so within the period of 

time allowed by this notice, you should 

advise the contact listed below as soon 

as possible. 

ADDRESSES: Direct all PRA comments to 

Nicole Ongele, FCC, via email PRA@

fcc.gov and to nicole.ongele@fcc.gov. 

FOR FURTHER INFORMATION CONTACT: For 

additional information about the 

information collection, contact Nicole 

Ongele, (202) 418–2991. 

Federal Communications Commission. 

Marlene Dortch, 

Secretary, Office of the Secretary. 

[FR Doc. 2022–06603 Filed 3–28–22; 8:45 am] 

BILLING CODE 6712–01–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisitions of Shares of a Bank or 

Bank Holding Company 

The notificants listed below have 

applied under the Change in Bank 

Control Act (Act) (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

applications are set forth in paragraph 7 

of the Act (12 U.S.C. 1817(j)(7)). 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in paragraph 7 of 

the Act. 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than April 13, 2022. 

A. Federal Reserve Bank of Chicago 

(Colette A. Fried, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414: 

1. Jeffrey Anderson, Minneapolis, 

Minnesota; Ronald Buholzer and Susan 

Buholzer, as co-trustees of the Ronald 

and Susan Buholzer Trust, Joshua 

Lincicum, Braytn Meythaler, and Merik 

Meythaler, all of Monroe, Wisconsin; 

Gregory Kranhenbuhl, as trustee of the 

Gregory K. Kranhenbuhl Survivors 

Trust, both of Newton, Wisconsin; 

Myron Meythaler and Linda Meythaler, 

as co-trustees of the Myron A. Meythaler 

and Linda L. Meythaler Revocable Trust, 

Connie Lincicum, Barry Meythaler, and 

Summer Stietz, all of South Wayne, 

Wisconsin; Brandi House, Verona, 

Wisconsin; Jason Lincicum, Lodi, 

Wisconsin; Jeremy Lincicum, Mt. Horeb, 

Wisconsin; and Robin Schubert, Warren, 

Illinois; as a group acting in concert to 

retain voting shares of Woodford 

Bancshares, Inc., and thereby indirectly 

retain voting shares of Woodford State 

Bank, both of Monroe, Wisconsin. 

Additionally, Jeffrey Anderson Family 

Trust, Jeffrey Anderson, as trustee, both 

of Minneapolis, Minnesota; to acquire 

voting shares of Woodford Bancshares, 

Inc., and thereby indirectly acquire 

voting shares of Woodford State Bank. 

2. Robert K. Ginther, as trustee of the 

Merlin E. Zitzner Trust fbo Jenele R. 

Zitzner, Merlin E. Zitzner, Jenele R. 

Zitzner, Alexander M. E. Zitzner, and 

Tara Zitzner, all of Baraboo, Wisconsin; 

as a group acting in concert, to retain 

voting shares of The Baraboo 

Bancorporation, Inc., and thereby 

indirectly retain voting shares of 

Baraboo State Bank, both of Baraboo, 

Wisconsin. 

Federal Reserve Bank of Kansas City 

(Jeffrey Imgarten, Assistant Vice 

President) 1 Memorial Drive, Kansas 

City, Missouri 64198–0001: 

1. Andrew R. Stull, Kearney, 

Nebraska, and Jody L. Weitzel, Dacono, 

Colorado; to join the Stull Family 

Group, a group acting in concert, to 

acquire voting shares of Farmers State 

Bancshares, Inc., and thereby indirectly 

acquire voting shares of Nebraska Bank, 

both of Dodge, Nebraska. 

Board of Governors of the Federal Reserve 

System, March 24, 2022. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–06586 Filed 3–28–22; 8:45 am] 

BILLING CODE P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 


lotter on DSK11XQN23PROD with NOTICES1
18018 Federal Register / Vol. 87, No. 60 / Tuesday, March 29, 2022 / Notices 

owned by the bank holding company, 

including the companies listed below. 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in the BHC Act 

(12 U.S.C. 1842(c)). 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than April 28, 2022. 

A. Federal Reserve Bank of Boston 

(Prabal Chakrabarti, Senior Vice 

President) 600 Atlantic Avenue, Boston, 

Massachusetts 02210–2204. Comments 

can also be sent electronically to 

BOS.SRC.Applications.Comments@

bos.frb.org: 

1. 1854 Bancorp, Cambridge, 

Massachusetts; to acquire Patriot 

Community Bank, Woburn, 

Massachusetts. 

Board of Governors of the Federal Reserve 

System, March 24, 2022. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–06585 Filed 3–28–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Supplemental Evidence and Data 

Request on Postpartum Home Blood 

Pressure Monitoring, Postpartum 

Treatment of Hypertensive Disorders 

of Pregnancy, and Peripartum 

Magnesium Sulfate Regimens for 

Preeclampsia With Severe Features 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Request for supplemental 

evidence and data submissions. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) is seeking 

scientific information submissions from 

the public. Scientific information is 

being solicited to inform our review on 

Postpartum Home Blood Pressure 

Monitoring, Postpartum Treatment of 

Hypertensive Disorders of Pregnancy, 

and Peripartum Magnesium Sulfate 

Regimens for Preeclampsia With Severe 

Features, which is currently being 

conducted by the AHRQ’s Evidencebased Practice Centers (EPC) Program. 

Access to published and unpublished 

pertinent scientific information will 

improve the quality of this review. 

DATES: Submission Deadline on or 

before April 28, 2022. 

ADDRESSES: 

Email submissions: epc@

ahrq.hhs.gov. 

Print submissions: 

Mailing Address: Center for Evidence 

and Practice Improvement, Agency for 

Healthcare Research and Quality, 

ATTN: EPC SEADs Coordinator, 5600 

Fishers Lane, Mail Stop 06E53A, 

Rockville, MD 20857. 

Shipping Address (FedEx, UPS, etc.): 

Center for Evidence and Practice 

Improvement, Agency for Healthcare 

Research and Quality, ATTN: EPC 

SEADs Coordinator, 5600 Fishers Lane, 

Mail Stop 06E77D, Rockville, MD 

20857. 

FOR FURTHER INFORMATION CONTACT: 

Jenae Benns, Telephone: 301–427–1496 

or Email: epc@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Agency for Healthcare Research and 

Quality has commissioned the 

Evidence-based Practice Centers (EPC) 

Program to complete a review of the 

evidence for Postpartum Home Blood 

Pressure Monitoring, Postpartum 

Treatment of Hypertensive Disorders of 

Pregnancy, and Peripartum Magnesium 

Sulfate Regimens for Preeclampsia With 

Severe Features. AHRQ is conducting 

this systematic review pursuant to 

Section 902 of the Public Health Service 

Act, 42 U.S.C. 299a. 

The EPC Program is dedicated to 

identifying as many studies as possible 

that are relevant to the questions for 

each of its reviews. In order to do so, we 

are supplementing the usual manual 

and electronic database searches of the 

literature by requesting information 

from the public (e.g., details of studies 

conducted). We are looking for studies 

that report on Postpartum Home Blood 

Pressure Monitoring, Postpartum 

Treatment of Hypertensive Disorders of 

Pregnancy, and Peripartum Magnesium 

Sulfate Regimens for Preeclampsia With 

Severe Features, including those that 

describe adverse events. The entire 

research protocol is available online at: 

https://effectivehealthcare.ahrq.gov/ 

products/hypertensive-disorderspregnancy/protocol. 

This is to notify the public that the 

EPC Program would find the following 

information on Postpartum Home Blood 

Pressure Monitoring, Postpartum 

Treatment of Hypertensive Disorders of 

Pregnancy, and Peripartum Magnesium 

Sulfate Regimens for Preeclampsia With 

Severe Features helpful: 

D A list of completed studies that 

your organization has sponsored for this 

indication. In the list, please indicate 

whether results are available on 

ClinicalTrials.gov along with the 

ClinicalTrials.gov trial number. 

D For completed studies that do not 

have results on ClinicalTrials.gov, a 

summary, including the following 

elements: Study number, study period, 

design, methodology, indication and 

diagnosis, proper use instructions, 

inclusion and exclusion criteria, 

primary and secondary outcomes, 

baseline characteristics, number of 

patients screened/eligible/enrolled/lost 

to follow-up/withdrawn/analyzed, 

effectiveness/efficacy, and safety results. 

D A list of ongoing studies that your 

organization has sponsored for this 

indication. In the list, please provide the 

ClinicalTrials.gov trial number or, if the 

trial is not registered, the protocol for 

the study including a study number, the 

study period, design, methodology, 

indication and diagnosis, proper use 

instructions, inclusion and exclusion 

criteria, and primary and secondary 

outcomes. 

D Description of whether the above 

studies constitute ALL Phase II and 

above clinical trials sponsored by your 

organization for this indication and an 

index outlining the relevant information 

in each submitted file. 

Your contribution is very beneficial to 

the Program. Materials submitted must 

be publicly available or able to be made 

public. Materials that are considered 

confidential; marketing materials; study 

types not included in the review; or 

information on indications not included 

in the review cannot be used by the EPC 

Program. This is a voluntary request for 

information, and all costs for complying 

with this request must be borne by the 

submitter. 

The draft of this review will be posted 

on AHRQ’s EPC Program website and 

available for public comment for a 

period of 4 weeks. If you would like to 

be notified when the draft is posted, 

please sign up for the email list at: 

https://www.effectivehealthcare.

ahrq.gov/email-updates. 

The systematic review will answer the 

following questions. This information is 

provided as background. AHRQ is not 

requesting that the public provide 

answers to these questions. 


lotter on DSK11XQN23PROD with NOTICES1